BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Tuplin EW, Holahan MR. Aripiprazole, A Drug that Displays Partial Agonism and Functional Selectivity. Curr Neuropharmacol 2017;15:1192-207. [PMID: 28412910 DOI: 10.2174/1570159X15666170413115754] [Cited by in Crossref: 23] [Cited by in F6Publishing: 28] [Article Influence: 5.8] [Reference Citation Analysis]
Number Citing Articles
1 Sumi S, Nagamine T, Sumi K, Aijima R, Oka K, Toyofuku A. Case report: Open bite as an extrapyramidal side effect with aripiprazole, a dopamine partial agonist. Front Psychiatry 2022;13:976387. [DOI: 10.3389/fpsyt.2022.976387] [Reference Citation Analysis]
2 Amani P, Habibpour R, Karami L. Characterizing aripiprazole and its ester derivatives, lauroxil and cavoxil, in interaction with dopamine D2 receptor: Molecular docking and dynamics simulations with physicochemical appraisals. Journal of Molecular Liquids 2022;362:119787. [DOI: 10.1016/j.molliq.2022.119787] [Reference Citation Analysis]
3 Gunasekera B, Wilson R, O'Neill A, Blest-Hopley G, O'Daly O, Bhattacharyya S. Cannabidiol attenuates insular activity during motivational salience processing in patients with early psychosis. Psychol Med 2022;:1-10. [PMID: 35775365 DOI: 10.1017/S0033291722001672] [Reference Citation Analysis]
4 Chen PY, Chang CK, Chen CH, Fang SC, Mondelli V, Chiu CC, Lu ML, Hwang LL, Huang MC. Orexin-a elevation in antipsychotic-treated compared to drug-free patients with schizophrenia: A medication effect independent of metabolic syndrome. J Formos Med Assoc 2022:S0929-6646(22)00110-3. [PMID: 35396156 DOI: 10.1016/j.jfma.2022.03.008] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Mandic-maravic V, Grujicic R, Milutinovic L, Munjiza-jovanovic A, Pejovic-milovancevic M. Dopamine in Autism Spectrum Disorders—Focus on D2/D3 Partial Agonists and Their Possible Use in Treatment. Front Psychiatry 2022;12:787097. [DOI: 10.3389/fpsyt.2021.787097] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
6 Tien Y, Huang H, Liao D, Huang S. Dose-response analysis of aripiprazole in patients with schizophrenia in Taiwan. Therapeutic Advances in Psychopharmacology 2022;12:204512532211132. [DOI: 10.1177/20451253221113238] [Reference Citation Analysis]
7 Gupta B, Chee KS, Neo LQ, Tang C, Hariram J, Tan GC, Verma S, Basu S, Appan DP, Ting CC, Abdin E, Lee J. Effect of aripiprazole as an adjunct to atypical antipsychotics on weight and metabolic profile: a 12-week open-label trial. Ther Adv Psychopharmacol 2021;11:20451253211046765. [PMID: 34646440 DOI: 10.1177/20451253211046765] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
8 Speyer H, Westergaard C, Albert N, Karlsen M, Stürup AE, Nordentoft M, Krogh J. Reversibility of Antipsychotic-Induced Weight Gain: A Systematic Review and Meta-Analysis. Front Endocrinol (Lausanne) 2021;12:577919. [PMID: 34393989 DOI: 10.3389/fendo.2021.577919] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
9 Mason K, Barnett J, Pappa S. Effectiveness of 2-year treatment with aripiprazole long-acting injectable and comparison with paliperidone palmitate. Ther Adv Psychopharmacol 2021;11:20451253211029490. [PMID: 34349980 DOI: 10.1177/20451253211029490] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
10 Wolfschlag M, Håkansson A. Increased risk for developing gambling disorder under the treatment with pramipexole, ropinirole, and aripiprazole: A nationwide register study in Sweden. PLoS One 2021;16:e0252516. [PMID: 34061895 DOI: 10.1371/journal.pone.0252516] [Reference Citation Analysis]
11 Torrisi SA, Laudani S, Contarini G, De Luca A, Geraci F, Managò F, Papaleo F, Salomone S, Drago F, Leggio GM. Dopamine, Cognitive Impairments and Second-Generation Antipsychotics: From Mechanistic Advances to More Personalized Treatments. Pharmaceuticals (Basel) 2020;13:E365. [PMID: 33167370 DOI: 10.3390/ph13110365] [Cited by in Crossref: 4] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
12 Madireddy S, Madireddy S. Regulation of Reactive Oxygen Species-Mediated Damage in the Pathogenesis of Schizophrenia. Brain Sci. 2020;10. [PMID: 33081261 DOI: 10.3390/brainsci10100742] [Cited by in Crossref: 5] [Cited by in F6Publishing: 15] [Article Influence: 2.5] [Reference Citation Analysis]
13 Grajales D, Ferreira V, Valverde ÁM. Second-Generation Antipsychotics and Dysregulation of Glucose Metabolism: Beyond Weight Gain. Cells 2019;8:E1336. [PMID: 31671770 DOI: 10.3390/cells8111336] [Cited by in Crossref: 26] [Cited by in F6Publishing: 34] [Article Influence: 8.7] [Reference Citation Analysis]
14 Berg KA, Clarke WP. Making Sense of Pharmacology: Inverse Agonism and Functional Selectivity. Int J Neuropsychopharmacol 2018;21:962-77. [PMID: 30085126 DOI: 10.1093/ijnp/pyy071] [Cited by in Crossref: 38] [Cited by in F6Publishing: 48] [Article Influence: 12.7] [Reference Citation Analysis]
15 Flanagan R, Lacasa L, Towlson EK, Lee SH, Porter MA, Bassett D. Effect of antipsychotics on community structure in functional brain networks. Journal of Complex Networks 2019;7:932-60. [DOI: 10.1093/comnet/cnz013] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
16 Stępnicki P, Kondej M, Kaczor AA. Current Concepts and Treatments of Schizophrenia. Molecules 2018;23:E2087. [PMID: 30127324 DOI: 10.3390/molecules23082087] [Cited by in Crossref: 72] [Cited by in F6Publishing: 107] [Article Influence: 18.0] [Reference Citation Analysis]
17 Azmanova M, Pitto-Barry A, Barry NPE. Schizophrenia: synthetic strategies and recent advances in drug design. Medchemcomm 2018;9:759-82. [PMID: 30108966 DOI: 10.1039/c7md00448f] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
18 Peng Y, McCorvy JD, Harpsøe K, Lansu K, Yuan S, Popov P, Qu L, Pu M, Che T, Nikolajsen LF, Huang XP, Wu Y, Shen L, Bjørn-Yoshimoto WE, Ding K, Wacker D, Han GW, Cheng J, Katritch V, Jensen AA, Hanson MA, Zhao S, Gloriam DE, Roth BL, Stevens RC, Liu ZJ. 5-HT2C Receptor Structures Reveal the Structural Basis of GPCR Polypharmacology. Cell 2018;172:719-730.e14. [PMID: 29398112 DOI: 10.1016/j.cell.2018.01.001] [Cited by in Crossref: 102] [Cited by in F6Publishing: 116] [Article Influence: 25.5] [Reference Citation Analysis]
19 Schübler M, Sadek B, Kottke T, Weizel L, Stark H. Synthesis, Molecular Properties Estimations, and Dual Dopamine D2 and D3 Receptor Activities of Benzothiazole-Based Ligands. Front Chem 2017;5:64. [PMID: 28955709 DOI: 10.3389/fchem.2017.00064] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]